President Trump looking at the solar eclipse

Solar Retinopathy: What may happen when you look at the solar eclipse without eye protection?

By reading this article, your agree that you have read the disclaimer at the end of this article, and agree with its contents in their entirety. Many of the millions of people who watched yesterday’s solar eclipse will have used proper eye protection before turning their gaze towards the spectacle in the sky. Others may have used

READ MORE…

Macular degeneration

Ophthotech Fovista AMD Phase 3 trials results come up short

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its Phase 3 clinical trial investigating the superiority of Fovista® (pegpleranib) anti-PDGF therapy in combination with Eylea® (aflibercept) or Avastin® (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of

READ MORE…

AMD

High rate of undiagnosed age-related macular degeneration (AMD) in primary eye care practices

A study finds high rate of underdiagnosis of age-related macular degeneration in primary eye care practices and advocates need for improved detection strategies. Age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment in older adults in the United States, yet little is known about whether AMD is appropriately diagnosed in primary eye

READ MORE…

Diabetic Retinopathy

Researchers identify new target for abnormal blood vessel growth in the eyes

A team led by Massachusetts Eye and Ear researchers has identified a novel therapeutic target for retinal neovascularization, or abnormal blood vessel growth in the retina, a hallmark of advanced diabetic eye disease. According to a report published online in Diabetes, the transcription factor RUNX1 was found in abnormal retinal blood vessels, and by inhibiting

READ MORE…

Cone-rod dystrophy

Researchers find causative factors in retinal dystrophies

Scientists from the Florida campus of The Scripps Research Institute have discovered how a protein called α2δ4 establishes proper vision. Their research helps explain why mutations in the gene encoding α2δ4 lead to retinal dystrophy, a disease characterized by defective color vision and night blindness. To study how this protein supports vision, the researchers modeled

READ MORE…

(c) Ophthotech

Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista ® in Wet AMD

Ophthotech Corporation has announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration

READ MORE…

Regenerating_mouse retinal ganglion cell

Visual Activity Regenerates Neural Connections Between Eye and Brain

A study in mice shows for the first time that high-contrast visual stimulation can help damaged retinal neurons regrow retinal ganglion cell axons. In combination with chemically induced neural stimulation, axons grew further than in strategies tried previously. Treated mice partially regained visual function. The study also demonstrates that adult regenerated central nervous system (CNS)

READ MORE…

Macular edema on OCT

Eylea outperforms Avastin for DME in patients with moderate vision loss

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that visual improvement was greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision.  Gains after two years were about the same for Eylea and Lucentis

READ MORE…